As a Free StocksGuide user, you can view scores for all 7,030 stocks worldwide.
8 Analysts have issued a Kazia Therapeutics Ltd Sponsored ADR forecast:
8 Analysts have issued a Kazia Therapeutics Ltd Sponsored ADR forecast:
| Dec '24 | 
         
    +/-
   
  
    %
   
 | 
      ||
| Revenue | 1.53 1.53 | 
         
      
        
        7,550%
      
      
        
        7,550%
      
 
        
       | 
      |
| Gross Profit | - - | 
         
    -
 
        
       | 
      |
| EBITDA | - - | 
         
    -
 
        
       | 
      |
| EBIT (Operating Income) EBIT | -20 -20 | 
         
      
        
        55%
      
      
        
        55%
      
 
        
       | 
      |
| Net Profit | -19 -19 | 
         
      
        
        81%
      
      
        
        81%
      
 
        
       | 
      |
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Kazia Therapeutics Ltd. engages in the pharmaceutical drug research and development. Its pipeline includes two clinical-stage drug development candidates such as GDC-0084, and Cantrixil. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.
| Head office | Australia | 
| CEO | John Friend | 
| Employees | 13 | 
| Founded | 1994 | 
| Website | www.kaziatherapeutics.com | 
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


